-
Je něco špatně v tomto záznamu ?
Effect of hexyloxy position on antagonistic properties of KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) at muscarinic acetylcholine receptors
A. Janoušková-Randáková, E. Mezeiová, J. Bláhová, N. Chetverikov, E. Dolejší, D. Nelic, L. Prchal, M. Novák, J. Korábečný, J. Jakubík
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- antagonisté muskarinových receptorů * farmakologie MeSH
- CHO buňky MeSH
- Cricetulus * MeSH
- pyridiny farmakologie chemie MeSH
- receptor muskarinový M1 metabolismus antagonisté a inhibitory MeSH
- receptory muskarinové metabolismus MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Antagonists with a long residence time at the receptors are desired for the possibility of reducing daily doses and side effects. KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) is the long-acting M1-preferring bitopic muscarinic antagonist with a half-life at muscarinic receptors of up to five hours. The binding of 2-hexyloxy and 3-hexyloxy analogues of KH-5 was simulated in silico, compounds were synthesized and their binding and antagonistic properties were measured experimentally in CHO cells expressing individual subtypes of muscarinic acetylcholine receptors. The overall binding affinities of the new compounds were similar to their respective parent compounds. Shifting the hexyloxy chain to ortho and meta positions led to a decrease in potency at the M1 receptor but an increase in potency at the M2 receptor and abolition of long-term antagonism. Preservation of the para position of the hexyloxy chain is essential for the further development of M1-preferring antagonists. Modifications of the basic centre may be the way to improve the geometry of antagonists towards long residence times to obtain the desired long-acting muscarinic antagonists in the future. The additional challenge for further development is the low metabolic stability of compounds.
Biomedical Research Centre University Hospital Hradec Kralove Hradec Kralove Czech Republic
Department of Neurochemistry Institute of Physiology Czech Academy of Sciences Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009314
- 003
- CZ-PrNML
- 005
- 20250429134850.0
- 007
- ta
- 008
- 250415e20250314fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2025.117977 $2 doi
- 035 __
- $a (PubMed)40088774
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Janoušková-Randáková, Alena $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 245 10
- $a Effect of hexyloxy position on antagonistic properties of KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) at muscarinic acetylcholine receptors / $c A. Janoušková-Randáková, E. Mezeiová, J. Bláhová, N. Chetverikov, E. Dolejší, D. Nelic, L. Prchal, M. Novák, J. Korábečný, J. Jakubík
- 520 9_
- $a Antagonists with a long residence time at the receptors are desired for the possibility of reducing daily doses and side effects. KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) is the long-acting M1-preferring bitopic muscarinic antagonist with a half-life at muscarinic receptors of up to five hours. The binding of 2-hexyloxy and 3-hexyloxy analogues of KH-5 was simulated in silico, compounds were synthesized and their binding and antagonistic properties were measured experimentally in CHO cells expressing individual subtypes of muscarinic acetylcholine receptors. The overall binding affinities of the new compounds were similar to their respective parent compounds. Shifting the hexyloxy chain to ortho and meta positions led to a decrease in potency at the M1 receptor but an increase in potency at the M2 receptor and abolition of long-term antagonism. Preservation of the para position of the hexyloxy chain is essential for the further development of M1-preferring antagonists. Modifications of the basic centre may be the way to improve the geometry of antagonists towards long residence times to obtain the desired long-acting muscarinic antagonists in the future. The additional challenge for further development is the low metabolic stability of compounds.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a CHO buňky $7 D016466
- 650 12
- $a Cricetulus $7 D003412
- 650 12
- $a antagonisté muskarinových receptorů $x farmakologie $7 D018727
- 650 _2
- $a receptory muskarinové $x metabolismus $7 D011976
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a receptor muskarinový M1 $x metabolismus $x antagonisté a inhibitory $7 D043643
- 650 _2
- $a pyridiny $x farmakologie $x chemie $7 D011725
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mezeiová, Eva $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Bláhová, Jana $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Chetverikov, Nikolai $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Dolejší, Eva $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Nelic, Dominik $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Prchal, Lukáš $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Novák, Martin $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Korábečný, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. Electronic address: jan.korabecny@fnhk.cz
- 700 1_
- $a Jakubík, Jan $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: jan.jakubik@fgu.cas.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 185 (20250314), s. 117977
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40088774 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134846 $b ABA008
- 999 __
- $a ok $b bmc $g 2310970 $s 1246395
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 185 $c - $d 117977 $e 20250314 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20250415